Considering that DCs contribute to metastatic spread by CD8+T cell responses and Treg activity regulation, ANXA1 can be considered a prognostic indicator of CRC metastasis and a possible target for immunomodulatory therapies [128,150]. The gene discussed is CD8A; the disease is colorectal carcinoma.